



COMUNICACIÓN DE INFORMACIÓN RELEVANTE 1NKEMIA IUCT GROUP, S.A.

En virtud de lo previsto en el artículo 17 del Reglamento (UE) nº 596/2014 sobre abuso de mercado y en el artículo 228 del texto refundido de la Ley del Mercado de Valores, aprobado por el Real Decreto Legislativo 4/2015, de 23 de octubre ponemos en su conocimiento el siguiente Hecho Relevante relativo a la sociedad **INKEMIA IUCT GROUP, S.A.** (en adelante “**InKemia**” o “**la Sociedad**” indistintamente).

Con motivo de la participación de la Compañía en el Foro Medcap 2017 organizado por Bolsas y Mercados Españoles, se adjunta la presentación corporativa que será utilizada en dicho foro que se celebrará los días 31 de Mayo y 1 de Junio de 2017

Atentamente,

En Mollet del Vallès, a 31 de mayo de 2017

Fdo: Josep Castells Boliart,
Consejero Delegado de 1NKEMIA IUCT GROUP, S.A.

A decorative graphic in the bottom-left corner featuring a cluster of colorful circles (orange, purple, red, green, blue, and red) containing various scientific icons such as a DNA helix, a pill, a flask, a mortar and pestle, a microorganism, and a petri dish. The background of this cluster is filled with a pattern of small, light gray scientific symbols including flasks, beakers, and molecular structures.

inkemia

IUCT group

Our knowledge at your service

Know-how

May, 2017

Introduction



Technological SME Holding founded in 1997.

High-tech business group whose activity centers on the **generation and exploitation of KNOW-HOW**, based on research and innovation for the development of new products, processes, services and technologies for the chemical, pharmaceutical, biotechnology, cosmeceutical and nutraceutical industries.

InKemia joined the **Spanish Stock Exchange** in 2012 in the expansion business segment in MAB with the **IKM Ticker**

Headquarters

- Mollet - Barcelona

Other facilities in Spain


- Tres Cantos - Madrid.
- Vilanova i la Geltrú - Barcelona

Foreign general subsidiaries:


- Sao Paulo - Brazil .
- Bogotá – Colombia
- Houston – USA
- London – UK



Multichannel Business Model



Group Structure



International Activity



- **International R & D Projects:**

- Projects with international companies, universities and R & D centers located in Europe, USA and South America.


- **International sales:**

- EU
- USA
- Latin America
- ASIA - Vietnam

- **Subsidiaries**

International subsidiaries develop locally certain R & D and technological activities.

- Inkemia Brazil (2014)
- Inkemia Colombia (2015)
- Inkemia Green Chemicals - USA (2016)
- Inkemia Advanced BF – UK (2016)



Inkemia in Numbers

GROUP:

- Knowledge Division
 - ✓ Full time employees: 68
 - ✓ Part time collaborators : 200
- Whole group
 - ✓ Full time employees : > 100
 - ✓ Part time collaborators : > 220

R & D Projects:

- More than 50 cooperative R & D.
- R & D Joint Ventures with more than 5 companies.

InKemia Pipeline

For the Chemical, Fine Chemical, Pharmaceutical, Nutraceutical and Cosmetic industries:

- 24 products
- 7 processes
- 18 technologies

Patents:

- Granted patents : 68 (26 families)
- Under evaluation patents: 150

Customers:

- Industrials +300
- Professionals trained > 10.000



Examples of industrial clients



A decorative graphic in the bottom-left corner featuring a cluster of colorful circles (orange, purple, red, green, blue, red) containing various scientific icons like a DNA helix, a pill, a flask, a mortar and pestle, a microorganism, and a petri dish. The background of this cluster is filled with a dense pattern of small, light-gray scientific symbols including beakers, flasks, and molecular structures.

inkemia

IUCT group

Our knowledge at your service

IUCT – KNOWLEDGE DIVISION

Know-how

Open Innovation/ Cooperation



R & D projects, more than 50 cooperative R & D in 18 years. Some examples :

- DISC-SCREEN Towards a fast biobased Discovery and Screening of new drugs targeting neoplastic and metastatic activity
- Solvsave (FP-5 2005-2009) Advanced safer solvents for Industrial Innovative Eco-processing
- Life (CDTI- 2011-2014). Discovery of new drugs for the treatment of breast cancer
- Orphan drugs (NGO -2011-2014). Discovery of new drugs for the treatment of hypotonic dystrophy
- Translink (FP7 - 2013-2017). Search for new drugs that prevent deterioration of bioprosthetic cardiac valves
- Ecobiofor (FP7 - 2014-2017). New solvents for paints and coatings from renewable sources
- GRAIL (FP7 – 2014-2018) Bio-Refinery using Glycerin as crude starting material
- CARBAZYMES (H2020 - 2015-2019) Sustainable industrial processes based on a C-C bond-forming enzyme platform.
- ERC-2015-Proof of Concept Grant (H2020 – 2016-2017) New target for antiangiogenic-resistant tumors .
- EPS-COLOMBIA (Colciencias – 2016-2017) Discovery and scaling-up the production of new EPS from Colombian microorganisms.
- N-H2L-Im (NUCLIS- Generalitat Catalunya - 2015-2017) Research of new drugs for the immune system.

R & D Collaborative projects

- Partners
 - ✓ Universities and R & D Labs
 - ✓ Industrial Companies
 - ✓ High Tech Companies
- R & D programmes
 - ✓ FP5 – FP7 and H2020 of EU
 - ✓ IberoEka
 - ✓ Regional and national programmes (UE)
 - ✓ Colombian programmes (COLCIENCIAS)




Open Innovation/ Cooperation

Join Ventures with other companies (co-development)

- BrainWave Discovery: Development of potential drugs for central nervous system diseases. 3 Hits in Parkinson.
- Bionos Biotech: Development cosmetic ingredient and dermatological active ingredients, for skin regeneration, anti-aging or antioxidant.
- Avidin Biotech: Development of potential drugs against breast, liver and lung cancers. Also, drugs for cardiovascular protection, neuroprotective, or cytoprotective endothelial function.
- Amylgen: Development of potential drugs against Alzheimer, improving memory, antidepressants or anxiolytics.
- Spanish Fine Chemical Association "AFAQUIM": Agreement for co-development projects with integrated companies in the association.

Technological Platforms:

- Green chemistry
- Drug discovery
- Industrial Biotechnology
- Drug Development
- High throughput analysis
- High throughput biosynthesis
- Chemical process optimization
- Preventox



A decorative graphic in the bottom-left corner featuring a cluster of colorful circles (orange, purple, red, green, blue, red) containing various scientific icons like a DNA helix, a pill, a flask, a mortar and pestle, a petri dish, and a microchip. The background of this cluster is filled with a pattern of small, light gray scientific symbols including beakers, flasks, and molecular structures.

inkemia

IUCT group

Our knowledge at your service


FINANCIALS

Know-how

InKemia - Value




Stock price



	Stock price	% of change	Negotiated €
21/12/2012	0,80		
31/12/2012	0,84	5,00%	125.000
31/12/2013	1,08	28,57%	3.986.000
31/12/2014	1,75	62,04%	13.977.000
31/12/2015	2,10	20,00%	6.401.000
31/12/2016	2,36	12,38%	12.947.000

Date	IKM Cap Value (million €)	IKM Value increase	Accumulated Value Increase
21/12/2012	16,76		
31/12/2012	17,56	5%	5%
31/12/2013	25,45	45%	52%
31/12/2014	45,36	78%	171%
31/12/2015	54,44	20%	225%
31/12/2016	61,18	11%	365%


IKM Cap Value (million €)




Financial summary 2015 -2016



**Consolidated Operative
Income 2016:
6.964.838 €**



**Consolidated
EBITDA 2016 :
999.751 €**



Invested Companies 2015 -2016



Invested Companies	Sales 2015	Sales 2016	Growth	Operative Income 2015	Operative Income 2016	Growth
<i>Vytrus Biotech, S.L.</i>	291.245	369.293	27%	730.115	840.774	15%
<i>Plasmia Biotach, S.L.</i>	30.000	25.187	-16%	284.242	128.364	-55%
<i>Mind the Byte, S.L.</i>	33.074	106.175	221%	263.231	395.667	50%
<i>Leanbio, S.L.</i>	147.411	244.219	66%	161.733	244.219	51%
<i>Pharmamel, S.L.</i>	1.262	130.170	10215%	1.262	253.770	20009%
<i>Recerca Clínica, S.L.</i>	586.520	574.552	-2%	586.520	574.552	-2%
<i>Arkyne Technologies, S.L. (Bioo)</i>	Not created	8.000		Not created	133.637	
<i>Kwolco Consciumers, S.L. (ABOUIT)</i>	Not created	-		Not created	71.321	
TOTAL	1.089.512	1.457.596	34%	2.027.103	2.642.304	30%



inkemia

IUCT group

Our knowledge at your service

ENTREPRENEURSHIP DIVISION

Know-how

Entrepreneurship division



- **Proprietary technologies Spin-offs**
 - ✓ Plasmia Biotech
 - ✓ MyoGem
- **Knowledge Capital Fund**
 - Group tool to invest in Start-Ups, university Spin-Offs and technological companies. Closer to an industrial investment than a VC.
 - ✓ Vytrus Biotech
 - ✓ LeanBio
 - ✓ Mind the Byte
 - ✓ PharmaMel
 - ✓ Abouit
 - ✓ Barcelona Ciència Capilar
 - ✓ Bioo
 - ✓ Arkyne
 - ✓ CIMER
 - ✓ Recerca Clínica
- **Technological companies associated to the group**
 - ✓ Barcelona BioScience
- **International subsidiaries**
 - Common international subsidiaries
 - ✓ Brazil
 - ✓ Colombia

- ✓ USA InKemia Green Chemicals
- ✓ UK InKemia Advanced BF

Disruptive Model of Value Growth



Questions to highlight

- **Is visible the value of the invested companies?**
 - Many do not consolidate with the group.
 - Other consolidated by equivalence, that not shown a complete picture of the value.
 - Few of them consolidate.
- **What is the value of the entrepreneurship division in the group?**
 - Global tech value. Network of synergic Life Science companies.
 - Scalability of the tech value for the inclusion of new companies to the network.
 - Participation in companies with a high potential growth in their value.
- **Is easy to highlight the value of these companies?**
 - Participate in companies in early stage development. They need time and hard work to reach the mature point.
 - The value is not easy to reflect in the financial accounts.
- **Must we disinvest to highlight this value?**
 - We would loose present and future technological and economical value.
 - A financial disinvestment would brake down the disruptive business model we want to create.
 - A disinvestment has sense if synergies.
- **How to highlight the value of the entrepreneurship division?**
 - The real value of the companies is what others are able to pay for them → Financial Markets.
 - Once they are ready for a stock exchange market → MAB, Alternext, AIM, Nasdaq



- Spin-off of the University of Barcelona.
- In 2012 InKemia enter in Vytrus capital (21%)
- Development and production of high added value plant active ingredients for the cosmetic and pharmaceutical use. Proprietary/own products and developments for others.
- Leader in **plant stem cells technology**.
- International network distribution: 50 countries worldwide.
- 2014: first own product “Arabian Cotton”
- 2015: 2 new own products “Luminia Granatum” and “Sensia Carota”
- 2016: 3 new own products.
- 2017: 1 new own product
- **IPO expected between 2018 and 2019**
- New capital round, pre-money value 7,3 million €



InKemia Advanced BF



Who is InKemia Advanced BF

- International subsidiary (UK) based in a specific knowledge area.
- Subsidiary focused in the exploitation of 2nd generation or advanced biofuels developed by InKemia.
- 15 years of R&D efforts.
- InKemia Advanced BF will have the exclusive licence of the patents developed by InKemia in this area.

The future

- Action plan:
 - Commissioning of industrial demonstration plant
 - Future business:
 - Building directly productions plants.
 - Licensing the technology to other producers.
 - Creating Joint Ventures with industrial partners
 - Create the company structure
 - Advance in R & D for new applications and the improvement of the technology

InKemia Advanced BF



Value of the company

- The value is exclusively the technology developed by InKemia and licensed to InKemia BF.
- Valuation Reports
 - Technical: Dr. Paul Brian, former Chevron Biofuels Technology vice-president “The product is among the most promising technologies in the biodiesel field that I have seen at this stage of development”.
 - Economic. The analysis and technology assessment KIMBCN provided a market valuation.
 - Financial Markets. WGP Global specialized in Corporate Finance and Regulated Financial Markets, conducted a study of comparable companies listed in the AIM market.
- Expected value
 - WGP Global, based on these reports determined a expected value of the company listed in the AIM.
 - Expected value: 50-60 Million British Pound.



WGP GLOBAL

1nKemia IUCT Group S.A.
C/Alvarez de Castro,63
08100 Mollet del Valles
Spain

David Orchard

Level 3
17 Hill Street
Mayfair
London, W1J SLJ

+44 20 3019 0500
+44 20 3019 0501
david.orchard@wgp.global
www.wgp.global



2 June 2016

Dear Sirs

Proposed Listing of 1nKemia Alternative BF Limited on London Alternative Investment Market (AIM)

In September 2015, WGP was retained on behalf of 1nKemia IUCT Group S.A. (IUCT) to advise upon and to facilitate the proposed admission to AIM of a new subsidiary company of IUCT.

For the above-mentioned purposes, WGP has incorporated a new limited liability company in England, 1nKemia Advanced BF Limited (IABF).

By the terms of an intended Licence and Technology Transfer Agreement which we have seen in its draft form (Agreement) IUCT proposes to grant to IABF certain licences and other rights to allow IABF to manufacture and commercialise the Product (as defined in the Agreement).

We have also been provided with a copy of an Assessment of the Product prepared in March 2016 by Dr. Paul Bryan an independent specialist consultant based in California, USA. We note that Dr. Bryan concludes his Assessment by stating:

An investment decision will necessarily involve many considerations outside the scope of this assessment, but my review indicates that the techno-economic prospects of [the Product] are sound. Indeed [the Product] is among the most promising technologies in the biodiesel field that I have seen at this stage of development.

Against the above background we have been asked to provide an indicative range of the potential opening market capitalisation of IABF immediately following a successful admission of its shares for trading on AIM taking into account as yet to be received valuation of the rights which will be granted by IUCT to IABF under the terms of the Agreement and assuming the date for such admission being prior to 31 December 2016.

It must be borne in mind that as at the date of this letter a specialist valuation on the value to IABF of the rights which are to be granted by IUCT under the Agreement is still awaited although we have had the benefit of being provided with a copy of a valuation of the Product prepared by Knowledge Innovation Market Invest dated 22 December 2011 on behalf of IUCT. Further, no Nominated Advisor, Nominated Broker or Reporting

WGP GLOBAL

Accountants have yet been appointed by IABF and no detailed financial projections, or working capital statements have been prepared for IABF. Consequently, we have not as yet had the benefit of any initial or long-form reports by Reporting Accountants nor any guidance from IABF's brokers on how best to frame IABF's share structure in order to achieve an optimal (but stable) opening share price. The brokers' views on these matters will also be influenced by market conditions immediately prior to the proposed listing and by the outcome of the anticipated pre-IPO fundraising. Also, the market capitalisation of IABF immediately following admission would also be impacted by such matters as the amount of shares in 'free-float'.

We make the above points to emphasise that any prediction on the likely market capitalisation of IABF must be heavily dependent on information which is not yet available and on factors which may affect its value or the market generally at the point of, or immediately following, admission of its shares to AIM.

Taking into account the significant limitations on information presently available to us and the absence of any input or guidance from other key advisors to IABF, we have nonetheless considered market conditions as they stand at the present time and have made certain assumptions regarding a potential range of valuations of the rights to be granted to IABF under the Agreement and a potential range of revenue streams that might be generated by IABF from exploitation of the Product. We have also extrapolated relevant performance statistics of other companies listed on AIM in a similar market sector to that of IABF.

Bearing in mind the above limitations and assumptions, our provisional view at the present time is that the market capitalisation of IABF immediately following the admission of its shares to AIM should be **between £50m and £60m (sterling)**

As this project continues to progress, we will keep this issue under constant review and advise you of any material changes in this preliminary assessment.

We hope that what we have said above is helpful and addresses the question you have put to us. Should you require any further elaboration on any point, however, please do not hesitate to let us know.

Finally, may we emphasise that this letter is written to IUCT in confidence and only for the purposes for which it was requested. It is given in good faith, and on the basis of the information available to WGP at today's date. WGP accepts no responsibility or liability for any loss or damage caused to IUCT or any third party as a result of any reliance being placed on it.

Yours faithfully

David J Orchard
For and on behalf of WGP Global Limited.



Our knowledge at your service



Pharmaceutical



Biotech



Cosmetic



Nutraceutical



Chemistry

COMPETITIVE R&D GRANTS

CONTRACT RESEARCH

CO-DEVELOPMENT PROJECTS

TECHNOLOGICAL SERVICES

CONSULTANCY

LINCENSING-OUT / TECHNOLOGY TRANSFER

TRAINING

KNOWLEDGE CAPITAL FUND



Thank you

Tel. +34 935793432

Email: cfo@inkemia.com